Author

A. J. MacCamy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

J. Feng· 2 shared K. W. Cohen· 2 shared L. Stamatatos· 2 shared M. Pancera· 2 shared A. B. Stuart· 1 shared A. T. McGuire· 1 shared C. E. Weidle· 1 shared C. N. Huynh· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. Feng

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

M. D. Gray, J. Feng, C. E. Weidle, K. W. Cohen, L. Ballweber-Fleming, A. J. MacCamy, C. N. Huynh, J. J. Trichka, D. Montefiori, G. Ferrari, M. Pancera, M. J. McElrath, L. Stamatatos

The paper identifies an antibody from a clinical trial that binds a different HIV-1 Env domain than VRC01-class antibodies and shows that epitope switching requires specific CDR changes.

bioRxiv · Aug 21, 2021Immunology

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

E. Seydoux, L. J. Homad, A. J. MacCamy, K. R. Parks, N. K. Hurlburt, M. F. Jennewein, N. R. Akins, A. B. Stuart, Y.-H. Wan, J. Feng, R. Nelson, S. Singh, K. W. Cohen, J. M. McElrath, J. A. Englund, , L. Stamatatos

This study characterizes neutralizing antibodies from a SARS-CoV-2 infected individual, finding that most antibodies are non-neutralizing and target epitopes outside the RBD, while two potent neutralizers bind the RBD with minimal mutation.

bioRxiv · May 12, 2020 · PreprintImmunology